RHN Partners with Sanome

The Royal Hospital for Neurodisability (RHN) is delighted to announce a partnership with Sanome – an AI and Health-Tech solution company. The partnership aims to develop an Early Warning System (EWS) with clinical utility for patients, and a research tool for Clinical Fellows. The RHN is a leading provider of specialist healthcare and neurorehabilitation services, serving patients with severe and complex neurodisability, and Sanome is committed to developing cutting-edge technology solutions to improve patient outcomes.

The two organisations are working together to enhance patient care by utilising Sanome’s translational science technology to develop an EWS with clinical utility. The piloted AI technology will provide healthcare professionals with tools to predict early signs of deterioration enabling them to better proactively manage the patient’s care plan. Nurses, clinicians, and therapists at RHN have played a critical and collaborative role in the co-design process, providing invaluable insights into the needs of their patients. They have shared their knowledge and expertise to ensure that the technology being developed meets the specific needs and requirements of staff and residents.

Furthermore, the partnership will also provide support to clinical fellows by developing a research database. This research database will serve as a valuable resource for researchers to investigate the complex needs of patients with severe neurological conditions and will help to inform the development of future treatments and interventions.

The partnership emphasises the commitment of both RHN and Sanome to provide innovative and effective patient care solutions. The EWS and the research database are scheduled to be developed over the next couple of years with the aim of improving the lives of patients with severe and complex neurodisability.

Dr Steven Luttrell, Medical Director of the RHN, said, “We are excited to announce our partnership with Sanome, which we are hopeful will allow us to provide care to our patients with even greater efficiency and convenience. At the Royal Hospital for Neuro-disability, we understand the role of advancing technology in enhancing patient care. We see great value in harnessing the power of new technology such as Sanome’s advanced diagnostic tools and translational care, with the ambition to deliver more personalised care to our patients and residents living with neuro-disability.”

Dr Sophie Duport, Associate Director of Research at the RHN, said, “The Royal Hospital for Neuro-disability has long been at the forefront of ground-breaking research and cutting-edge therapies for patients with complex neurological conditions. I am excited to see the potential for Sanome’s technology to contribute to our understanding of the various neurological conditions we encounter. Through this partnership, we hope to not only improve patient outcomes but also advance the field of neurological research.”

Benedikt von Thüngen, CEO of Sanome commented, “We are thrilled to partner with the RHN, one of the most respected centres of specialist neurorehabilitation services. The development of an Early Warning System and a research database for clinical fellows will provide clinicians with the ability to predict and manage patient deterioration and ultimately significantly improve the patient outcomes.”